✦ LIBER ✦

Prostate-specific antigen and screening for prostate cancer

✍ Scribed by Han, Misop; Gann, Peter H; Catalona, William J

Book ID: 122605082
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 470 KB
Volume: 88
Category: Article
ISSN: 0025-7125
DOI: 10.1016/S0025-7125(03)00188-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prostate Specific Antigen—a Screening Te

Prostate Specific Antigen—a Screening Test for Prostatic Cancer?

✍ C. S. POWELL; A. M. FIELDING; K. ROSSER; A. C. AMES; K. C. VAUGHTON 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

PROSTATE-SPECIFIC ANTIGEN SCREENING FOR

PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION-ANALYTICAL PERSPECTIVE

✍ Julia H. Hayes; Michael J. Barry; Philip W. Kantoff; James E. Stahl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Overdetection, overtreatment and costs i

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

✍ Heijnsdijk, E A M; der Kinderen, A; Wever, E M; Draisma, G; Roobol, M J; de Koni 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 281 KB

Prostate-specific antigen-based screenin

Prostate-specific antigen-based screening for prostate cancer: Evidence, controversies and future perspectives

✍ Kazuto Ito 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Can Prostate-Specific Antigen and Prosta

Can Prostate-Specific Antigen and Prostate-Specific Antigen Velocity Be Used for Prostate Cancer Screening in Men Older Than 70 Years?

✍ Vladimir Mouraviev; Gloria Broadwater; Leon Sun; Janice M. Mayes; Judd W. Moul; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Prostate-specific antigen: A surrogate e

Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?

✍ Schr�der, Fritz H.; Kranse, Ries; Barbet, Nik; Hop, Wim C.J.; Kandra, Albert; La 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 2 views

BACKGROUND. An endpoint for clinical trials of prostate cancer which simplifies traditional endpoints (response of measurable lesions, progression rates, and death) is urgently needed. This is especially true for hormone-unresponsive disease, for which many new drugs are presently in a development p